Drug Profile
Research programme: asthma/allergy therapy - Amgen
Alternative Names: Asthma/allergy research programme - AmgenLatest Information Update: 14 Aug 2001
Price :
$50
*
At a glance
- Originator Amgen
- Class
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Hypersensitivity
Most Recent Events
- 14 Aug 2001 No-Development-Reported for Allergy in USA (PO)
- 14 Aug 2001 No-Development-Reported for Asthma in USA (PO)
- 07 Feb 2001 Kinetix Pharmaceuticals has been acquired by Amgen